Horizon Therapeutics Public Limited Company

HZNP

IE00BQPVQZ61

Horizon Therapeutics plc Provides Earnings Guidance for the Full Year 2022

March 01, 2022 at 07:00 am EST

Horizon Therapeutics plc provided earnings guidance for the full year 2022. For the year, the company expects net sales to range between $3.9 billion and $4.0 billion, representing 22% growth at the midpoint.

Latest news about Horizon Therapeutics Public Limited Company

Health Canada Approves Horizon Therapeutics plc 's UPLIZNA® (inebilizumab for injection) for the Treatment of Neuromyelitis Optica Spectrum Disorders	Jan. 16	CI
Global markets live: Boeing, Amgen, Microsoft, Volkswagen, Tesla...	23-10-09
Horizon Therapeutics Public Limited Company Announces the Cessation of Member of the Board of Directors	23-10-06	CI
Amgen completes $27.8 bln Horizon deal	23-10-06	RE
Amgen Completes Acquisition of Horizon Therapeutics	23-10-06	MT
Amgen completes acquisition of Horizon Therapeutics	23-10-06	RE
Horizon Therapeutics Public Limited Company(NasdaqGS:HZNP) dropped from NASDAQ Composite Index	23-10-06	CI
Horizon Therapeutics Public Limited Company(NasdaqGS:HZNP) dropped from FTSE All-World Index	23-10-06	CI
Horizon Therapeutics Public Limited Company(NasdaqGS:HZNP) dropped from S&P Global BMI Index	23-10-06	CI
Horizon Therapeutics Public Limited Company(NasdaqGS:HZNP) dropped from S&P TMI Index	23-10-06	CI
Horizon Therapeutics Public Limited Company(NasdaqGS:HZNP) dropped from S&P Biotechnology Select Industry Index	23-10-06	CI
Horizon Therapeutics Public Limited Company's Equity Buyback announced on September 9, 2022, has expired.	23-10-05	CI
Amgen Inc. completed the acquisition of Horizon Therapeutics Public Limited Company.	23-10-05	CI
Amgen Wins Irish Court Approval to Acquire Horizon Therapeutics	23-10-05	MT
Horizon Therapeutics Public Limited Company(NasdaqGS:HZNP) dropped from NASDAQ Biotechnology Index	23-10-05	CI
Horizon Therapeutics Public Limited Company Announces New Analysis of Adhering to Uninterrupted Full Course of Treatment with Tepezza to Support Thyroid Eye Disease Patient Outcomes	23-09-29	CI
EMEA Morning Briefing : Shares Seen Lower at Start of the Week	23-09-25	DJ
Nvidia, Amgen back AI-driven drug firm Generate:Biomedicines' $273 mln fundraise	23-09-14	RE
Horizon Therapeutics, Q32 Bio Say First Patient Dosed in Phase 2 Trial of Bempikibart in Severe Alopecia Areata	23-09-13	MT
Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart for Severe Alopecia Areata	23-09-13	CI
FTC settlement could shelter Amgen from US price cuts, taxes	23-09-05	RE
Global markets live: Arm, Amgen, Lloyds, Novo Nordisk, Nestlé...	23-09-04
News Highlights : Top Company News of the Day	23-09-03	DJ
Health Care Up as Traders Hedge on Growth Views -- Health Care Roundup	23-09-01	DJ
Sector Update: Health Care Stocks Rising in Late Afternoon Trading	23-09-01	MT

Chart Horizon Therapeutics Public Limited Company

Duration

Period

Chart Horizon Therapeutics Public Limited Company

More charts

Company Profile

Horizon Therapeutics plc is an Ireland-based global biotechnology company. The Company is focused on the discovery, development and commercialization of medicines that address the critical needs of people impacted by rare, autoimmune and severe inflammatory diseases. The Companyâs portfolio of medicines include ACTIMMUNE, BUPHENYL (sodium phenylbutyrate), PROCYSBI (cysteamine bitartrate), Prescription RAVICTI (glycerol phenylbutyrate), and other. ACTIMMUNE is part of a drug regimen used to treat Chronic Granulomatous Disease (CGD). BUPHENYL (sodium phenylbutyrate) is a tablet for oral administration and BUPHENYL (sodium phenylbutyrate) Powder for oral, nasogastric, or gastrostomy tube administration contains sodium phenylbutyrate. PROCYSBI (cysteamine bitartrate) delayed-release capsules and delayed-release oral granules is a prescription medicine used to treat nephropathic cystinosis in adults and children 1 year of age and older.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+30.38%	684B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.36%	361B
MERCK & CO., INC.	+19.30%	329B
ABBVIE INC.	+3.73%	284B
ASTRAZENECA PLC	+16.70%	240B
NOVARTIS AG	+8.78%	208B
ROCHE HOLDING AG	-7.93%	200B
AMGEN INC.	+7.68%	166B

Other Pharmaceuticals